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ABSTRACT
The cap-dependent translation is frequently deregulated in a variety of 
cancers associated with tumor progression. However, the molecular basis of the 
translation activation for metastatic progression of cancer remains largely elusive. 
Here, we demonstrate that activation of cap-dependent translation by silencing the 
translational repressor 4E-BP1 causes cancer epithelial cells to undergo epithelial-
mesenchymal transition (EMT), which is associated with selective upregulation of the 
EMT inducer Snail followed by repression of E-cadherin expression and promotion of 
cell migratory and invasive capabilities as well as metastasis. Conversely, inhibition 
of cap-dependent translation by a dominant active mutant 4E-BP1 effectively 
downregulates Snail expression and suppresses cell migration and invasion. 
Furthermore, dephosphorylation of 4E-BP1 by mTORC1 inhibition or directly targeting 
the translation initiation also profoundly attenuates Snail expression and cell motility, 
whereas knockdown of 4E-BP1 or overexpression of Snail significantly rescues the 
inhibitory effects. Importantly, 4E-BP1-regulated Snail expression is not associated 
with its changes in the level of transcription or protein stability. Together, these 
findings indicate a novel role of 4E-BP1 in the regulation of EMT and cell motility 
through translational control of Snail expression and activity, and suggest that 
targeting cap-dependent translation may provide a promising approach for blocking 
Snail-mediated metastatic potential of cancer.
INTRODUCTION
The cap-dependent translation is a process by 
which most capped mRNAs are translated into proteins. 
This process is limited by translation initiation, a step 
controlled by the eIF4F complex at the level of ribosomal 
recruitment. The eIF4F complex is assembled by the 
translation initiation factor eIF-4E that binds to the 5’-
cap structure of mRNAs, the scaffolding protein eIF4G 
and the RNA helicase eIF4A [1]. Emerging evidence 
indicates that translation of certain key oncogenic mRNAs 
bearing long and highly structured 5’-untranslated regions 
(UTR), such as those encoding proliferation- and survival-
promoting proteins including cyclins, VEGF, c-Myc, 
Bcl-2 and survivin, is strongly dependent on the eIF-4E. 
Consequently, these oncogenic mRNAs are selectively 
and disproportionately affected by eIF4E availability and 
are sensitive to the alteration in the levels of eIF4E [2, 
3]. Overexpression of eIF4E is frequently observed in 
a variety of human cancers. In addition, another major 
mechanism for regulation of eIF4E function is involved in 
the eIF4E-binding proteins, 4E-BPs. 4E-BP1 (the major 
epithelial cell form) is a member of the 4E-BP family 
that represses translation by competing with eIF4G for 
binding to eIF4E, thereby preventing formation of the 
eIF4F complex. In cancer cells, however, 4E-BP1 is 
frequently hyperphosphorylated by its upstream oncogenic 
signals such as PI3K/AKT and RAS/RAF/MEK/ERK 
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pathways, which causes 4E-BP1 disassociation from 
eIF4E and thus inactivates 4E-BP1 function and increases 
the level of free eIF4E. The mTOR kinase complex 1 
(mTORC1), a downstream target of both AKT and ERK 
signaling [4, 5], is a master regulator of eIF4E-initiated 
cap-dependent translation by phosphorylating 4E-BP1 
on Thr37 and Thr46 that act as priming sites for its 
subsequent phosphorylation on Ser65 and Thr70 [6]. 
Hyperphosphorylation of 4E-BP1 or reduction of 4E-BP1 
expression is associated with malignant progression and 
poor prognosis [3, 7-9], whereas dephosphorylation of 
4E-BP1 has been identified as an important biomarker for 
predicting response to anti-cancer therapy [10, 11]. These 
findings have indicated that deregulation of 4E-BP1-
controlled cap-dependent translation can contribute to 
cancer progression and support the development of agents 
that target 4E-BP1 phosphorylation or eIF-4E. 
Snail (Snail1) is a zinc-finger transcription factor 
that functions as a key transcriptional repressor in 
inhibiting E-cadherin expression [12, 13]. E-cadherin is 
a transmembrane glycoprotein that mediates epithelial 
intercellular junctions. Downregulation of E-cadherin 
is a hallmark of epithelial-mesenchymal transition 
(EMT) during embryonic development, a process also 
exploited by invasive cancer cells [14, 15]. During EMT, 
epithelial tumor cells lose their epithelial polarity and 
cell-cell adhesion and gain mesenchymal phenotypes 
with increased migratory and invasive capabilities. It has 
long been believed that EMT is initiated at the advanced 
stage of tumor progression and is a prerequisite for tumor 
cell dissemination and metastasis [14, 15]. Numerous 
experimental systems showed that Snail represses 
E-cadherin expression and induces EMT in different type 
of cancer cells, indicating that Snail plays a fundamental 
role in EMT and cancer metastasis [14, 15]. Indeed, there 
is a considerable inverse correlation between Snail and 
E-cadherin expression in a variety of epithelial tumors. 
Overexpression of Snail or reduced E-cadherin expression 
correlates with higher tumor grade, nodal metastasis and 
tumor recurrence, and predicts poor clinical outcomes in 
patients with various cancers [12-15]. Snail expression is 
induced by a wide range of signaling pathways including 
TGFβ, Notch and Wnt pathways and hypoxia stress [16]. 
Phosphorylation of Snail by GSK3β and PAK1 plays 
an important role in regulation of its stability, cellular 
localization and function [17, 18]. However, little is 
known about whether Snail is regulated at the level of 
translation.
In the present study, we demonstrate that activation 
of cap-dependent translation by loss of 4E-BP1 function in 
cancer cells selectively upregulates Snail expression and 
enhances its functions on EMT, cell migration/invasion 
and metastasis. Our study uncovers an important aspect of 
translational regulation of Snail in controlling cell motility 
and metastatic potential of cancer.
RESULTS
Reduction of 4E-BP1 expression induces EMT, 
upregulates Snail expression and promotes cancer 
cell migration, invasion and metastasis
4E-BP1 expression has been shown to be inversely 
correlated with tumor progression in colorectal, breast 
and other cancers [8-10]. To investigate the functional 
importance and molecular basis of 4E-BP1-regulated 
cap-dependent translation in cancer progression, we 
generated HCT116 colon cancer cell derivatives with 
stable knockdown of 4E-BP1 expression by shRNA. As 
compared to the morphology of HCT116 cells or HCT116 
cells expressing control shRNA under a light microscope, 
we surprisingly observed that knockdown of 4E-BP1 
expression caused HCT116 cells acquired fibroblastic-
like characteristics, as they demonstrated a more elongated 
morphology and a scattered density, whereas the isogenic 
controls or parental cells exhibited higher degree of 
adherence between neighboring cells (Figure 1A). Similar 
results were also observed in silencing 4E-BP1 expression 
in DLD1 colon cancer cells (Supplementary Figure 1A). 
The observed alterations are characteristic features of 
EMT. The loss of E-cadherin is considered to be the most 
fundamental event during EMT [14, 15]. Intriguingly, we 
found that cells (HCT116, DLD1, SW480, BT474) with 
stable knockdown of 4E-BP1 expression demonstrated 
a marked reduction in the level of E-cadherin protein 
(Figure 1B and Supplementary Figure 1B). To understand 
how E-cadherin was downregulated by 4E-BP1 
knockdown, we determined the expression of several 
key transcriptional factors known to facilitate EMT by 
repression of E-cadherin. Remarkably, the expression of 
Snail, a direct transcriptional repressor of E-cadherin, 
was dramatically upregulated in those cells with 4E-BP1 
knockdown (Figure 1B and Supplementary Figure 1B). 
In contrast, expression of other E-cadherin transcriptional 
repressors such as Slug (Snail2) and Twist was unaffected. 
Emerging evidence indicates that induction of EMT by 
Snail contributes cells granted with motility and invasion 
capacities [14, 15]. We thus examined the effect of 4E-BP1 
knockdown on cell migration and invasion using Boyden 
chamber assays as we described previously [19]. As shown 
in Figure 1C, D, HCT116 cells with 4E-BP1 knockdown 
exhibited a three- to five-fold increase in both migratory 
and invasive capacities compared with the control cells. 
Similar results were also obtained in three other colon 
cancer cell lines (DLD1, HT29, SW480) and three 
breast cancer cell lines (MDA-MB-231, MDA-MB-468, 
BT474) in which 4E-BP1 gene was silenced (Figure 
1D, migration data not shown). To determine whether 
the increased migratory and invasive abilities of cancer 
cells by 4E-BP1 knockdown facilitate cancer metastasis, 
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we used an experimental liver metastasis model of colon 
cancer in vivo as we described previously [19]. Luciferase 
and GFP-labeled HCT116 cells with stable 4E-BP1 
knockdown were injected intrasplenically into athymic 
nude mice. Formation of liver metastasis was assessed 
by bioluminescent and fluorescent imaging. Compared 
to the HCT116 cells expressing control shRNA, silencing 
4E-BP1 expression markedly promoted liver metastases 
in mice (Figure 1E, F). Collectively, these results suggest 
that 4E-BP1 loss selectively upregulates Snail protein 
expression for EMT induction and subsequently enhances 
cancer cell migration and invasion as well as metastasis. 
Dephosphorylated 4E-BP1 inhibits Snail 
expression and cancer cell migration and invasion
Loss of 4E-BP1 expression or hyperphosphorylation 
of 4E-BP1 is known to lead to activation of cap-dependent 
translation [1]. To ascertain the role of cap-dependent 
translation in the regulation of Snail expression and 
cell migration and invasion, 4E-BP1 wild-type (wt) 
and its mutant 4E-BP1-4A, in which the four known 
phosphorylation sites (T37, T46, S65, T70) were replaced 
with alanine were ectopically expressed in HCT116 
cells. We showed previously that the mutant 4E-BP1-
4A cannot be phosphorylated and binds constitutively to 
eIF4E, thus inhibits cap-dependent translation, whereas 
expression of 4E-BP1 wt had no such effects due to its 
hyperphosphorylation in HCT116 cells [11]. As compared 
to 4E-BP1 wt and vector control, expression of the 
dominant active 4E-BP1-4A mutant profoundly repressed 
expression of Snail but not Slug and Twist (Figure 2A), 
and additionally inhibited cell migration and invasion 
as we showed previously [19]. Similar results were also 
obtained in MDA-157 breast cancer cells by expression 
of the active 4E-BP1-4A mutant (Supplementary Figure 
2). To further confirm the role of 4E-BP1 in regulation 
of Snail activity, 4E-BP1 wt and 4A were re-expressed 
in HCT116-4E-BP1 knockdown cells. Consistent with 
Figure 1: Silencing of 4E-BP1 induces EMT, upregulates Snail expression, and enhances cancer cell migration, invasion 
and metastasis. (A) For morphological comparison, HCT116 cells alone or with stable expression of control (Ctrl) shRNA or 4E-BP1 
shRNA cells were photographed using a light microscope. Scale bar = 200 µm. (B) HCT116 cells alone or with stable expression of Ctrl 
shRNA or 4E-BP1 shRNA were immunoblotted with the indicated antibodies. (C) Transwell migration analysis of HCT116 cells with stable 
expression of Ctrl shRNA or 4E-BP1 shRNA over 6 h. The results represent the mean number of migrated cells per field ± S.E.M. (n=3). 
Scale bar = 500 µm. (D) The invasive ability of various cancer cell lines with stable expression of Ctrl shRNA or 4E-BP1 shRNA. The 
results are expressed as the fold change of cell invasion in Sh 4E-BP1 cells relative to the Sh Ctrl cells and presented as means ± S.E.M. 
(n=3). (E) Bioluminescence and GFP images of liver metastasis in athymic nude mice injected intrasplenically with HCT116-Luc/GFP 
cells expressing Ctrl shRNA or 4E-BP1 shRNA at week 3 post-injection. (F) Quantitative analysis of bioluminescence in liver metastasis 
as shown in (E) (n=6 mice/group). * P < 0.02 for Sh 4E-BP1 versus Sh Ctrl.
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our previous findings [11] and the results as indicated 
above, expressed 4E-BP1-4A bound constitutively to 
eIF4E-mRNA cap complex and markedly inhibited 
Snail expression attendant with a dramatic increase in 
the level of E-cadherin and suppression of cell invasion 
(Figure 2B, C and D). In contrast, 4E-BP1 wt was highly 
phosphorylated at the four phosphorylation sites; only 
slightly bound to eIF4E-mRNA cap complex; and thus 
had much less inhibitory effect on Snail expression and 
cell invasion than those induced by 4E-BP1-4A. These 
data suggest that the phosphorylation status of 4E-BP1 
is associated with its function on the regulation of Snail 
expression and its activity. 
The mTOR kinase forms two distinct functional 
complexes, mTORC1 and mTORC2. mTORC1 is a master 
regulator of cap-dependent translation by phosphorylation 
of 4E-BP1, whereas mTORC2 regulates AKT activity 
through phosphorylation of AKT on Ser473 [20]. 
Rapamycin is a modest inhibitor of mTORC1 activity 
and mTOR kinase inhibitors are much more effective 
than rapamycin in inhibiting 4E-BP1 phosphorylation 
[21, 22]. Using a clinical-grade ATP-site mTOR kinase 
inhibitor AZD8055 [23], we explored whether mTORC1 
inhibition also suppresses Snail expression and cancer cell 
migration and invasion. As shown in Figure 3A, B and 
Supplementary Figure 3, AZD8055 effectively inhibited 
phosphorylation of 4E-BP1 at the four phosphorylation 
sites in the three tested cell lines (HCT116, MDA-MB-468 
and MDA-MB-231). Inhibition of 4E-BP1 phosphorylation 
in these cells was associated with downregulation of Snail 
expression accompanied by an increase in E-cadherin 
expression upon AZD8055 exposure within 24 h (Figure 
3A). In contrast, AZD8055 had no effect on the expression 
of other E-cadherin regulators, Slug and Twist, or a 
recently reported Snail regulator, Y-box binding protein 
1 (YB-1) [24]. As compared to AZD8055, rapamycin, an 
allosteric inhibitor of mTORC1, only weakly inhibited 
4E-BP1 phosphorylation and had much less repression 
on Snail expression and cell invasion (Figure 3B, C 
and D). Since AZD8055 also inhibited mTORC2 as 
indicated by loss of p-AKT on S473 (Figure 3A, B), we 
investigated whether inhibition of AKT by AZD8055 is 
associated with reduction of Snail expression. Treatment 
with MK2206, a selective AKT inhibitor [25], effectively 
inhibited AKT phosphorylation but did not affect 4E-
BP1 phosphorylation, Snail expression and cell invasion 
in HCT116 and MDA-468 cells (Figure 3B, C and D). 
Furthermore, knockdown of rictor, a key component of 
mTORC2 [26], inhibited p-AKT but had no effect on Snail 
expression (Figure 3E). However, depletion of raptor, 
an obligatory component of mTORC1 [27], markedly 
repressed 4E-BP1 phosphorylation, Snail expression and 
cell invasion (Figure 3E, F). Conversely, activation of 
mTORC1 by silencing its upstream repressor TSC2 [28] 
enhanced 4E-BP1 phosphorylation, Snail expression and 
cell invasion (Figure 3G, H), although mTROC1 activation 
Figure 2: A dominant active 4E-BP1 mutant profoundly inhibits Snail expression and cell invasion. (A) Immunoblot 
analysis of HCT116 cells with stable expression of vector, HA-4E-BP1 WT or HA-4E-BP1 4A. (B, C) HCT116-4E-BP1 knockdown (KD) 
cells were re-expressed with vector, HA-4E-BP1 WT or HA-4E-BP1 4A. Cell lysates were immunoblotted with the indicated antibodies 
or precipitated with m7GTP sepharose beads followed by immunoblotting of HA, 4E-BP1 and eIF4E. (D) Transwell invasion analysis of 
HCT116-4EBP1 KD cells with re-expressing vector, HA-4E-BP1 WT or HA-4E-BP1 4A over 30 h. The results represent the mean number 
of invaded cells per field ± S.E.M. (n=3). * P < 0.02 for 4E-BP1 4A versus 4E-BP1 WT or vector.
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Figure 3: mTORC1 plays a critical role in the regulation of Snail expression and cancer cell motility. (A) HCT116 or 
MDA-MB-468 cells were treated with 500 nM AZD8055 for the indicated times. Cell lysates were immunoblotted with the indicated 
antibodies. (B) HCT116 or MDA-MB-468 cells were treated with 50 nM rapamycin. 500 nM AZD8055, 1 µM MK2206 or dimethyl 
sulfoxide (DMSO) as control for 12 h. Cell lysates were immunoblotted with the indicated antibodies. (C, D) Transwell invasion analysis 
of HCT116 and MDA-MB-468 cells in the presence of the drugs as indicated in (B) for 30 h (C) and 24 h (D), respectively. The results 
represent the mean number of invaded cells per field ± S.E.M. (n=3). * P < 0.03 for AZD8055 versus DMSO control, rapamycin or 
MK2206. (E) HCT116 cells alone or with stable expression of Ctrl shRNA, raptor shRNA or rictor shRNA were immunoblotted with the 
indicated antibodies. (F) Transwell invasion analysis of HCT116 cells with stable expression of Ctrl shRNA or raptor shRNA over 30 h. (G) 
Immunoblot analysis of HCT116 cells with stable expression of Ctrl shRNA or TSC2 shRNA. (H) Transwell invasion analysis of HCT116 
cells with stable expression of Ctrl shRNA or TSC2 shRNA over 30 h. The results (F, H) represent the mean number of invaded cells per 
field ± S.E.M. (n=3). # P < 0.03 for Sh raptor or Sh TSC2 versus Sh Ctrl.
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by TSC2 knockdown induced feedback inhibition of 
AKT that was consistent with the previous reports 
[29, 30]. Taken together, these results indicate that the 
mTORC1/4E-BP1 signaling axis plays an indispensable 
role in the regulation of Snail expression and migratory/
invasive capacities of cancer cells.
mTORC1/4E-BP1 signaling regulates Snail 
expression and its activity at the level of 
translation
To understand how mTORC1/4E-BP1 signaling 
regulates Snail expression, we first determined the 
level of Snail mRNA by quantitative real-time reverse 
transcription-PCR (RT-PCR). As compared to the 
upregulation of Snail protein expression elicited by 4E-
BP1 knockdown in HCT116 cells (Figure 1B), there 
was not a significant change in the level of Snail mRNA 
between 4E-BP1 knockdown and control cells (Figure 
4A). However, the level of E-cadherin mRNA in the 4E-
BP1 knockdown cells was inhibited by about 50% (Figure 
4A), which was associated with its decreased protein 
expression (Figure 1B). These data suggest that 4E-BP1 
translationally regulates Snail expression and secondarily 
affects its transcriptional targets such as E-cadeherin. 
This notion was further supported by the results showing 
that downregulation of Snail protein by inhibition of 
cap-dependent translation with 4E-BP1 4A (Figure 2A) 
or the mTOR kinase inhibitor AZD8055 (Figure 3A, B) 
was not associated with its change in the level of mRNA 
(Figure 4B, C). In addition, using a cap-dependent 
translation reporter luciferase (Luc) mRNA linked to 
the 5’-UTR of Snail for measurement of cap-dependent 
Snail translation activity, we found that the 5’-UTR of 
Snail-Luc translation activity was inhibited (30-37%) by 
AZD8055 in HCT116 cells or HCT116 cells expressing 
control shRNA, but silencing 4E-BP1 expression that 
Figure 4: The regulation of Snail expression by mTORC1 is through 4E-BP1-mediated cap-dependent translation 
mechanism. (A) Quantitative RT-PCR analysis of mRNA expression of Snail or E-cadherin relative to β-actin in HCT116 cells with stable 
expression of Ctrl shRNA or 4E-BP1 shRNA (n=3). (B) Quantitative RT-PCR analysis of mRNA expression of Snail relative to β-actin in 
HCT116 cells with stable expression of vector, HA-4E-BP1 WT or HA-4E-BP1 4A (n=3). (C) Quantitative RT-PCR analysis of mRNA 
expression of Snail relative to β-actin in HCT116 cells that were treated with 500 nM AZD8055 or DMSO as control for 24 h (n=3). (D) 
HCT116 cells alone or with stable expression of Ctrl shRNA or 4E-BP1 shRNA were transfected with a bicistronic luciferase reporter that 
detects cap-dependent translation of the Renilla luciferase gene linked to the 5’-UTR of Snail and cap-independent Polio IRES-mediated 
translation of the firefly luciferase gene. The transfected cells were treated with 500 nM AZD8055 or DMSO as control for 12 h. Luciferase 
activities were measured by a dual-luciferase assay, and the Renilla/firefly luciferase luminescence ratio was calculated for cap-dependent 
translational activity. The results are expressed as the inhibition of cap-dependent translation relative to the DMSO-treated controls and 
presented as means ± S.E.M. (n=3). (E) Immunoblot analysis of HCT116 cells with stable expression of Ctrl shRNA or 4E-BP1 shRNA that 
were treated with or without 500 nM AZD8055 for 12 h. (F) HCT116 cells were treated with 500 nM AZD8055 or DMSO as control for 
30 min, followed by addition of 20 µg/ml cycloheximide (CHX) for the indicated times. Cell lysates were immunoblotted with Snail and 
β-actin antibodies. (G) Immunoblots of Snail as shown in (F) were quantified using the FluorChem digital imaging system (Alpha Innotech, 
Santa Clara, CA). The level of Snail remaining was obtained by normalizing β-actin level at each time, and the results are presented as mean 
± S.E.M. (n=3). * P < 0.03 for Sh 4E-BP1 versus Sh Ctrl.
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Figure 5: Snail is an important effector of mTORC1/4E-BP1 signaling responsible for translational control of cancer 
cell migration and invasion. (A) Immunoblot analysis of HCT116 cells with expression of vector or HA-tagged Snail. (B, C) Migration 
(B) or invasion (C) analysis of HCT116 cells with expression of vector or Snail. (D) Invasion analysis of HCT116 cells with expression 
of vector or Snail in the presence of 500 nM AZD8055 or DMSO as control for 30 h. (E) Invasion analysis of HCT116 cells with stable 
expression of control shRNA, raptor shRNA or raptor shRNA with co-expressing Snail over 30 h. (F) Invasion analysis of HCT116 cells 
with stable expression of vector, 4E-BP1 4A or 4E-BP1 4A with co-expressing Snail over 30 h. (G, H) HCT116 cells with stable expression 
of Ctrl shRNA or 4E-BP1 shRNA were transfected with control siRNA or Snail siRNA for 48 hours, followed by immunoblot analysis with 
the indicated antibodies (G) and invasion analysis over 30 h (H). Data shown in graphs represent the mean ± S.E.M. (n=3). * P < 0.02.
Figure 6: The translation initiation inhibitor 4EGI-1 effectively suppresses Snail expression and migratory and invasive 
capacities of cancer cells. (A) Immunoblot analyses of the indicated cells that were treated with 50 µM 4EGI-1 for the indicated times. 
(B) Quantitative RT-PCR analysis of mRNA expression of Snail relative to β-actin in the indicated cells that were treated with 50 µM 4EGI-
1 or DMSO as control for 24 h (n=3). (C) Migration analysis of HCT116 cells in the presence of 4EGI-1 with the indicated concentrations 
for 6 h. (D) Invasion analysis of HCT116, MDA-MB-468 and MDA-MB-231 cells in the presence of 50 µM 4EGI-1 or DMSO as control 
for 30 h, 24 h and 20h, respectively. (E) Invasion analysis of HCT116 cells with expression of vector or Snail in the presence of 50 µM 
4EGI-1 or DMSO as control for 30 h. Data shown in graphs represent the mean ± S.E.M. (n=3). * P < 0.03.
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activates cap-dependent translation significantly rescued 
the inhibitory effect (Figure 4D). Moreover, knockdown 
of 4E-BP1 expression markedly reversed the decreased 
expression of Snail protein attendant with the increased 
expression of E-cadherin, and reduced the inhibitory 
effect of AZD8055 on cell invasion (Figure 4E and 
Supplementary Figure 4). Additionally, we found that the 
decreased Snail expression by AZD8055 was not due to 
the change in its protein stability as analyzed by protein 
degradation rate using cycloheximide chase assay (Figure 
4F, G). Collectively, these data indicate that mTORC1 
regulates Snail expression and its activity largely through 
4E-BP1-mediated cap-dependent translation mechanism.
Snail mediates the effects of mTORC1/4E-BP1 
signaling on translational control of cancer cell 
migration and invasion
The importance of Snail downregulation in 
mediating the effects of the mTORC1/4E-BP1 pathway 
inhibition was determined in HCT116 cells in which Snail 
protein was exogenously overexpressed (Figure 5A). 
These cells did not exhibit changes in cell proliferation 
(data not shown) but showed a two- to three-fold increase 
in cell migration and invasion compared with the vector 
control cells (Figure 5B, C). Furthermore, in these cells, 
the effect of mTROC1 inhibition elicited by AZD8055 or 
raptor knockdown on suppression of cell invasion was 
profoundly reduced compared with that in the control 
cells (Figure 5D, E). In addition, overexpression of Snail 
could also reverse a decreased cell invasion induced by 
the cap-dependent translation inhibitor 4E-BP1 4A (Figure 
5F). Conversely, silencing Snail expression 48 h after 
transfection with siRNA markedly inhibited cell invasion 
in both control and 4E-BP1 knockdown cells, although 
4E-BP1 knockdown upregulated Snail expression and 
promoted cell invasion (Figure 5G, H). Thus, these data 
suggest that Snail plays a critical role in mediating the 
effects of mTORC1/4E-BP1 signaling on translational 
control of cell migration and invasion.
Targeting translation initiation with 4EGI-1 
blocks Snail expression and cancer cell migration 
and invasion 
To further confirm that the cap-dependent translation 
is required for Snail expression, a selective eIF4E/eIF4G 
interaction inhibitor, 4EGI-1 that blocks assembly of 
eIF4F translation initiation complex [31], was tested 
in HCT116, MDA-MB-468 and MDA-MB-231 cells. 
As shown in Figure 6A, 4EGI-1 inhibited Snail protein 
expression in all three cell lines 12 h after drug exposure 
and profoundly by 24 h. However, the level of Snail 
mRNA was unaffected by 4EGI-1 (Figure 6B). Similar 
to the findings obtained from mTORC1 inhibition or 
repression of cap-dependent translation by 4E-BP1 4A on 
cell motility (Figures 2 and 3), 4EGI-1 could also inhibit 
cancer cell migration in a dose dependent manner (Figure 
6C). Furthermore, 4EGI-1 markedly inhibited invasive 
capability of HCT116, MDA-MB-468 and MDA-MB-231 
cells (Figure 6D), but overexpression of Snail could 
largely prevent the inhibitory effects (Figure 6E). These 
data suggest that exploring a small molecular inhibitor to 
directly target eIF4F translation initiation complex could 
represent an alternative strategy for suppression of Snail 
expression and metastatic potential of cancer. 
DISCUSSION
In this study, we provide substantial evidence 
to support the notion that the 4E-BP1-regulated cap-
dependent translation plays an active role in EMT 
induction, tumor cell migration and invasion via the 
selective increased translation of Snail accompanied by 
its transcriptional repression of E-cadherin expression. 
Our study demonstrates a distinctive mechanism for the 
regulation of Snail and its activities in the process of 
cancer metastasis.
Migration and invasion are critical steps in the 
initial progression of cancer that facilitate metastasis. 
Emerging evidence shows that Snail-induced EMT 
via downregulation of E-cadherin is associated with 
Figure 7: A schematic model for the role of 
mTROC1/4E-BP1 signaling axis in the translational 
control of Snail and its biological consequences. 
Arrowheads represent activation; bar-headed lines represent 
inhibition. * mutation.
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increased migratory and invasive capabilities, and the 
subsequent systemic spread of cancer cells [14, 15]. 
The expression of Snail has been shown to correlate 
significantly with disease relapse and poor prognosis in 
patients with breast, colorectal and ovarian carcinomas 
[12-15]. Many studies have demonstrated that Snail 
is tightly regulated at the transcriptional level by an 
integrated and complex signaling network including the 
PI3K/AKT, RAS/RAF/MEK/ERK, RhoGD12, TGFβ/
Smad, Notch, Wnt/β-catenin and NFκB pathways [16, 32]. 
In addition, expression of Snail and its function are also 
shown to be regulated by posttranslational modifications. 
GSK-3β, negatively regulated by AKT, has been shown to 
phosphorylate Snail, leading to its subcellular localization 
and degradation [17]. Early studies showed that inhibition 
of PI3K/AKT signaling with the PI3K inhibitors, 
wortmannin and LY294002, release the suppression of 
GSK-3β, which leads to subsequent degradation of Snail 
[17, 33]. However, using the selective AKT inhibitor 
MK2206 as we and others reported previously [19, 25], we 
found that inhibition of AKT has no effect on Snail mRNA 
and protein expression in colon and breast cancer cells 
(Figure 3B and Supplementary Figure 5). These findings 
are further confirmed by silencing the AKT upstream 
regulator, rictor (Figure 3E). Given that wortmannin and 
LY294002 can also inhibit other PI3K-related enzymes 
such as mTOR [34, 35], it is thus reasonable to speculate 
that mTOR may involve in the regulation of Snail 
expression and its activity. Our data show that Snail, 
but not other EMT inducers such as Slug and Twist, is 
specifically downregulated with concomitant increased 
expression of E-cadherin by the pharmacologic or genetic 
inhibition of mTORC1, whereas aberrant activation of 
mTORC1 by TSC2 knockdown exhibits opposite effect. 
Notably, the decreased expression of Snail by mTORC1 
inhibition is not associated with changes in the level of 
transcription or protein stability. Mechanistically, we 
identify that the cap-dependent translation repressor 4E-
BP1 functions as a key effector of mTROC1 activation on 
translational control of Snail expression and its subsequent 
activities as noted by the transcriptional repression of 
E-cadherin, induction of EMT and promotion of migration 
and invasion in colon and breast cancer cells (Figure 7). In 
addition, disruption of cap-dependent translation initiation 
complex with the selective eIF4E/eIF4G interaction 
inhibitor 4EGI-1 shows a profound inhibition on Snail 
expression as well as migratory and invasive abilities of 
cancer cells. Thus, our findings indicate that Snail activity 
could be regulated in AKT-independent but mTORC1/4E-
BP1-mediated cap-dependent translation initiation 
mechanism.
A recent report by Evdokimova and colleagues 
[24] suggested that YB-1 is positively involved in the 
regulation of Snail expression via cap-independent 
translation associated with breast cancer aggressiveness, 
as they showed that inhibition of mTORC1-mediated 
cap-dependent translation with rapamycin does not affect 
Snail levels in YB-1-expressing premalignant MCF10AT 
human mammary epithelial cells. YB-1 is highly 
expressed in multiple human malignancies including 
breast and colorectal cancers [36]. Although our data 
also show that rapamycin has negligible effect on Snail 
expression and cell invasion in breast and colon cancer 
cells, we found that the insignificant effect is associated 
with the weak inhibition of mTORC1-mediated 4E-BP1 
phosphorylation by rapamycin. First, we showed that as 
compared with rapamycin, both mTOR kinase inhibitor 
AZD8055 and/or specific inhibition of mTORC1 by 
raptor knockdown exhibit potent inhibition of 4E-BP1 
phosphorylation; and both also effectively repress Snail 
expression and its subsequent activities in colon and breast 
cancer cell lines with highly expressed YB-1 (Figure 3). 
Second, the non-phosphorylated mutant 4E-BP1-4A 
with constitutive inhibition of cap-dependent translation 
also profoundly inhibits Snail expression and cell 
motility (Figure 2), as well as colon cancer metastasis, 
as we reported recently[19]. Third, silencing 4E-BP1 
expression significantly rescues translational inhibition of 
Snail and cell invasion by AZD8055 (Figure 4D, E and 
Supplementary Figure 4). More importantly, the decreased 
level of Snail by mTORC1 inhibition is not associated 
with changes in the level of YB-1 expression (Figure 
3A and Supplementary Figure 3). Taken together, these 
data further support the conclusion that mTORC1/4E-
BP1 signaling plays a crucial role in the cap-dependent 
translational regulation of Snail and its biologic 
consequences during the metastatic progression of cancer. 
Our findings are consistent with recent reports [37-
39] showing the role of mTORC1 in the EMT process 
and translational control of gene expression program 
for cancer progression. However, a more recent study 
reported conflicting results. Using normal immortalized 
human epithelial cell lines and primary epithelial cells, 
Mikaelian and colleagues [40] showed that genetic and 
pharmacologic inhibition of mTORC1 triggers EMT 
associated with upregulation of ZEB1, known to activate 
EMT, but these effects are not found in cancer-driven cell 
lines including the MDA-MB-231 breast cancer cell line 
as we used in this study. Indeed, we found that mTORC1 
inhibition represses EMT process in colon and breast 
cancer cells by specific inhibition of Snail translation 
attendant with increased expression of the epithelial 
marker E-cadherin, thus suppressing cancer cell migration 
and invasion. This discordant effect of mTORC1 inhibition 
on EMT and cell motility is probably dependent on the 
mutational status of the cells. Mutations in genes that 
encode components of the PI3K/AKT and RAS/RAF/
MEK/ERK pathways occur at high frequency in cancers 
including colon and breast cancers [41-43]. We and others 
have recently shown that mTORC1/4E-BP1 axis largely 
mediates the effects of the mutational activation of AKT 
and ERK signaling pathways on translational control of 
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cancer cell motility and metastasis[19] [11, 39]. Thus, it 
is possible that tumors with mutational activation of AKT 
and ERK pathways are highly dependent on mTORC1/4E-
BP1 signaling for the promotion of EMT, cell motility 
and metastasis (Figure 7). Our data suggest that targeting 
mTROC1 with the ATP-site mTOR kinase inhibitors 
that can effectively activate 4E-BP1 repressive function 
on cap-dependent translation may provide a promising 
treatment strategy for blocking metastatic progression of 
cancer. Many mTOR kinase inhibitors are in early clinical 
testing. The anti-metastatic effect of these inhibitors and 
their potential side effect on EMT induction in normal 
cells should now be evaluated in detail in the clinical 
studies.
Our results also suggest that directly targeting 
assembly of eIF4F translation initiation complex 
(Figure 6) may be an effective alternative to the mTOR 
kinase inhibitors or combination of AKT and MEK 
kinase inhibitors as we showed recently [11, 19]. Given 
the importance of 4E-BP1-regulated cap-dependent 
translation as a common downstream node that integrates 
multiple oncogenic signaling pathways for tumor growth 
and metastasis [11, 19, 44], compounds that mimic 4E-
BP1 biochemical function by disruption of eIF4E-eIF4G 
interaction or target other translation initiation components 
may be effective for cancer therapeutics. Indeed, several 
of those translation initiation inhibitors, including eIF4E 
antisense-oligonucleotides and silvestrol that inhibits the 
RNA helicase eIF4A, have recently produced encouraging 
anti-tumor effects with limited toxicity profiles in mouse; 
and some of these inhibitors have been tested in clinical 
studies [45-48]. Considering an accumulation of damaging 
side effects from a combination of therapies that inhibits 
several canonical signaling pathways impinging upon 
translation initiation, and the mTOR inhibition-induced 
feedback activation of upstream receptors and AKT 
signaling that may reduce anti-tumor effects of mTOR 
inhibitors [49-52], targeting cap-dependent translation 
that could simultaneously block upstream oncogenic 
signals and their downstream targets would hold potential 
as a future therapeutic strategy against the metastatic 
progression of cancer. 
MATERIALS AND METHODS
Cell culture, plasmids, siRNA and shRNA
Human colon and breast cancer cell lines were 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA) and maintained in the appropriate 
medium with supplements as suggested by ATCC. 
MK2206, rapamycin and AZD8055 were obtained from 
Selleck (Houston, TX). The pcDNA3.1-HA-tagged 
human Snail expression plasmid and the human raptor 
and rictor shRNA expression plasmids were purchased 
from Addgene (Cambridge, MA). The specificity of the 
targeting raptor and rictor sequences has been verified 
and described previously [26]. The human 4E-BP1 and 
TSC2 shRNA expression plasmids were from Open 
Biosystems (Lafayette, CO) and the specificity of the 
targeting sequences has been verified in our previous 
study [19]. siRNA pool against human Snail (L-010847) 
or non-targeting control siRNA pool (D-001810-10) was 
obtained from Dharmacon (Chicago, IL). For establishing 
stable transfectants with knockdown of specific protein 
expression, cell lines were lentivirally infected with the 
indicated shRNA construct followed by selection with 
puromycin (2 µg/ml) for one week. HCT116 or HCT116-
4E-BP1 knockdown cells with stable expression of 
HA-tagged 4E-BP1 and 4E-BP1-4A were generated as 
described previously [11]. 
Migration and invasion assays
Migration and invasion assays were performed 
in Boyden chambers with coated collagen or Matrigel, 
respectively, as instructed by the manufacturer (BD 
Biosciences, San Jose, CA) and described previously 
[19]. Briefly, cells were added to the upper chamber of 
the transwell insert. Completed medium containing 10% 
FBS as chemoattractant was added to the bottom chamber. 
To assess the effect of kinase inhibitors on cell migration 
and invasion, the inhibitors or their vehicle control DMSO 
were added to the bottom chamber medium. The plates 
were incubated at 37°C in 5% CO2 for indicated time 
points. After incubation, cells in the upper compartment 
were removed with a cotton swab, and cells that migrated 
or invaded to the filter surface facing the bottom chamber 
were fixed in 4% paraformaldehyde and stained with 0.2% 
crystal violet. The numbers of migrated or invaded cells 
were counted in at least four areas at x 40 magnification 
using an inverted microscope. All experiments were 
performed at least twice in triplicate.
Immunoblot analysis
Cells were lysed in NP-40 lysis buffer as described 
previously [11]. Equal amounts of total protein were 
resolved by SDS-PAGE, transferred to membranes, 
immunoblotted with specific primary and secondary 
antibodies and detected using chemiluminescence (GE 
Healthcare Bio-Sciences, Pittsburgh, PA). Antibodies for 
p-AKT(S473), p-4E-BP1(T37/46), p-4E-BP1(S65), p-4E-
BP1(T70), 4E-BP1, eIF4E, Snail, Slug, YB-1, raptor, 
rictor and TSC2 were from Cell Signaling Technology 
(Danvers, MA). E-cadherin antibody (67A4) was from 
Santa Cruz Biotechnology (Dallas, TX). HA antibody 
was from Novus Biologicals (Littleton, CO) and -actin 
antibody was from Sigma (St Louis, MO).
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Quantitative RT-PCR
Total cellular RNA was isolated using the RNeasy 
plus mini kit (Qiagen, Valencia, CA). Equal amounts of 
RNA were used as templates for all reactions. Double-
stranded cDNA was generated by using the SuperScript III 
First Strand Synthesis System (Life Technologies, Grand 
Island, NY). Real-time PCR reactions were carried out 
with specific probes for human Snail (Hs00195591_m1), 
E-cadherin (Hs01023894_m1) and β-actin (#4352935E) 
using the StepOne Real-Time PCR system (Applied 
Biosystems, Foster City, CA).
Cycloheximide (CHX) chase assay
Cells were treated with CHX (20 µg/ml) and 
harvested at indicated time points. The cells were lysed in 
NP-40 lysis buffer and equal amounts of total protein were 
analyzed by immunoblot. To examine the effect of mTOR 
inhibition, one set of cells was pretreated with AZD8055 
for 30 min before the addition of CHX.
Cap-Binding Assay
Cell lysates as prepared above were incubated with 
m7GTP sepharose beads (GE Healthcare Bio-Sciences) 
to capture eIF4E and its binding partners. Precipitates 
were washed three times with lysis buffer, resuspended in 
2x Laemmli sample buffer, and resolved by SDS-PAGE 
followed by immunoblot with the indicated antibodies.
Quantification of cap-dependent translation
The 5’-UTR cDNAs of human Snail were obtained 
by RT-PCR from a HCT116 cDNA library using the 
primers as described in Supplementary Table 1. These 
5’-UTR cDNAs were each inserted immediately 
upstream from the translation start codon of the renilla 
luciferase gene in the bicistronic luciferase reporter vector 
pcDNA3-rLuc-PolioIRES-fLuc, which directs cap-
dependent translation of the renilla luciferase gene and 
cap-independent Polio IRES-mediated translation of the 
firefly luciferase gene [53]. All sequences were verified 
by automated sequencing. Cells (80,000) were transfected 
with each the constructed bicistronic luciferase reporter 
plasmid (0.2 µg) in 12-well plates using X-tremeGENE 
Transfection Reagent (Roche Applied Science, 
Indianapolis, IN). After 24 h transfection, cells were 
treated with kinase inhibitors for the indicated times, and 
cell lysates were assayed for renilla luciferase and firefly 
luciferase activities as described [11]. Cap-dependent 
renilla activity was normalized against cap-independent 
firefly activity as the internal control. The renilla/firefly 
luciferase luminescence ratio was calculated for cap-
dependent translational activity.
Animal studies
Male athymic nude mice (5-6 weeks old) were 
purchased from Taconic (Hudson, NY, USA) and 
maintained and treated under specific pathogen-free 
conditions. The experimental liver metastasis assay was 
described previously [19]. Briefly, cells with co-expression 
of firefly luciferase and GFP were injected into the spleen 
(5×106/mouse) of athymic nude mice (n=6 per group). 
To monitor metastasis, mice were imaged with luciferase 
signals using the IVIS Spectrum (Caliper Life Science, 
Hopkinton, MA, USA) and results were analyzed by 
Living Image 3.0 software. In addition, the liver metastatic 
lesions were further examined by GFP imaging.
Statistical analysis
All experiments were carried out in at least twice. 
Results are expressed as mean ± S.E.M. where applicable. 
A two-tailed Student’s t-test was used to compare the 
intergroup. Differences between groups were considered 
statistically significant at P < 0.05. 
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